医学
回顾性队列研究
内科学
心脏病学
CTD公司
室间隔
结缔组织病
肺动脉高压
心力衰竭
队列
接收机工作特性
曲线下面积
射血分数
疾病
心室
自身免疫性疾病
海洋学
地质学
作者
Yue Zhang,Xiaohui Wang,Xiaoxuan Sun,Zhangdi Zhou,Dongyu Li,Yixin Zhang,Qi Hu,Linwei Shan,Jiayi Dai,Huangshu Ye,Lei Zhou,Yinsu Zhu,Qiang Wang
标识
DOI:10.1093/rheumatology/keaf140
摘要
Abstract Objectives The primary objective of this study is to investigate the potential of cardiovascular magnetic resonance (CMR) parameters to augment prognostic evaluation in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH). Methods A retrospective, single-center cohort study was conducted on 110 patients with CTD-PAH who were diagnosed via right heart catheterization between 2017 and 2023. These patients underwent CMR examinations based on clinical indications. Results : After a mean follow-up period of 27 months, 27 patients experienced clinical deterioration events. After adjusting for age, sex, and COMPERA 2.0 risk assessment model parameters, five CMR metrics were identified as independent risk factors for clinical deterioration in CTD-PAH patients. ROC curve analysis showed that combining COMPERA 2.0 risk assessment model with CMR metrics improved predictive performance, with interventricular septum extracellular volume (IVS ECV) providing the greatest benefit among tissue metrics and right ventricular ejection fraction (RVEF) showing the most improvement among right heart function metrics. KM survival curves revealed that patients with RVEF < 39.2% and IVS ECV > 31.4% had the poorest prognosis. Calibration curves indicated that integrating RVEF and IVS ECV significantly enhanced the accuracy and reliability of the COMPERA 2.0 risk assessment model in predicting 1-year, 2-year, and 3-year events-free survival rates in CTD-PAH patients, with the C-index improving from 0.626–0.805. Conclusion Combining RVEF and IVS ECV with COMPERA 2.0 risk assessment model significantly enhances the model's predictive accuracy for clinical deterioration in CTD-PAH patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI